Sweat testing for cystic fibrosis. Diagnostic screening with a combination chloride ion-selective electrode

Area of Science:

• Neonatal screening
• Pediatric diagnostics
• Medical device technology

Background:

• Cystic fibrosis (CF) is a genetic disorder requiring early diagnosis.
• Newborn screening aims to identify infants with CF shortly after birth.
• Sweat chloride testing is a primary diagnostic method for CF.

Purpose of the Study:

• To evaluate the Orion Skin Chloride Measuring System for newborn screening.
• To assess the impact of procedural innovations on sweat chloride measurements.
• To determine the optimal timing for sweat chloride testing in neonates.

Main Methods:

• Utilized the Orion Skin Chloride Measuring System for sweat analysis.
• Incorporated procedural innovations to optimize sweat collection and measurement.
• Conducted measurements on newborn infants, including those with confirmed cystic fibrosis.

Main Results:

• Diagnostic screening for cystic fibrosis is achievable with the Orion system.
• Insufficient sweating in very young infants necessitates testing on day 2 of life or later.
• Measurements from two infants with cystic fibrosis were analyzed.

Conclusions:

• The Orion Skin Chloride Measuring System is suitable for newborn cystic fibrosis screening.
• Optimal test performance requires adequate infant sweating, achieved on day 2 or later.
• Early detection of cystic fibrosis through sweat chloride testing is crucial for timely intervention.